We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-2.35%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.85B
AUM Growth
+$132M
Cap. Flow
+$223M
Cap. Flow %
7.84%
Top 10 Hldgs %
64.12%
Holding
111
New
25
Increased
23
Reduced
13
Closed
26

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$172M
2
MET icon
MetLife
MET
+$21.3M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$13.5M
4
AIG icon
American International
AIG
+$13.4M
5
DG icon
Dollar General
DG
+$13M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$32.6M
2
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$28.1M
3
IMGN
Immunogen Inc
IMGN
+$13.7M
4
BABA icon
Alibaba
BABA
+$12.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.93M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 28.65%
2 Healthcare 21.49%
3 Financials 2.87%
4 Communication Services 1.25%
5 Industrials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HAPN
51
Happen Inc
HAPN
$2.16B
$8.86M 0.31%
+70,000
New +$8.84M
TWX
52
DELISTED
Time Warner Inc
TWX
$8.54M 0.3%
+100,000
New +$7.97M
SLB icon
53
CALL
SLB Ltd
SLB
$74.9B
$8.54M 0.3%
100,000
– –
AVNR
54
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$8.47M 0.3%
500,000
-500,000
-50% -$7.03M
COF icon
55
CALL
Capital One
COF
$130B
$8.26M 0.29%
100,000
– –
MBLY
56
DELISTED
Mobileye N.V.
MBLY
$8.11M 0.28%
200,000
+100,000
+100% +$4.69M
HAL icon
57
CALL
Halliburton
HAL
$26.4B
$7.87M 0.28%
+200,000
New +$9.73M
APTV icon
58
CALL
Aptiv
APTV
$12.5B
$7.27M 0.26%
100,000
– –
HOUS
59
CALL
DELISTED
Anywhere Real Estate
HOUS
$6.67M 0.23%
150,000
– –
ACOR
60
CALL
DELISTED
Acorda Therapeutics
ACOR
$6.13M 0.22%
1,250
+417
+50% +$1.79M
PCYC
61
CALL
DELISTED
PHARMACYCLICS INC
PCYC
$6.11M 0.21%
50,000
– –
IMGN
62
CALL
DELISTED
Immunogen Inc
IMGN
$6.1M 0.21%
1,000,000
+600,000
+150% +$5.49M
HOUS
63
DELISTED
Anywhere Real Estate
HOUS
$5.56M 0.2%
+125,000
New +$5.19M
JUNO
64
DELISTED
Juno Therapeutics, Inc.
JUNO
$5.22M 0.18%
+100,000
New +$4.48M
HLT icon
65
Hilton Worldwide
HLT
$71.9B
$5.22M 0.18%
+66,667
New +$5M
DAL icon
66
Delta Air Lines
DAL
$57.6B
$4.92M 0.17%
100,000
-200,000
-67% -$8.42M
LCTX icon
67
Lineage Cell Therapeutics
LCTX
$262M
$4.78M 0.17%
+1,588,475
New +$4.3M
FCX icon
68
CALL
Freeport-McMoran
FCX
$85.7B
$4.67M 0.16%
200,000
– –
MRTX
69
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.63M 0.16%
250,000
– –
XOMA
70
DELISTED
Xoma
XOMA
$4.31M 0.15%
60,000
+10,000
+20% +$857K
WFT
71
CALL
DELISTED
Weatherford International plc
WFT
$4.01M 0.14%
+350,000
New +$5.24M
XOMA
72
CALL
DELISTED
Xoma
XOMA
$3.88M 0.14%
54,000
+14,000
+35% +$1.2M
OIH icon
73
CALL
VanEck Oil Services ETF
OIH
$2B
$3.59M 0.13%
+5,000
New +$4.16M
IRWD icon
74
Ironwood Pharmaceuticals
IRWD
$614M
$3.32M 0.12%
258,954
– –
ALLY icon
75
Ally Financial
ALLY
$13.4B
$2.95M 0.1%
+125,000
New +$2.83M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2014 Portfolio in Review

As of Q4 2014, Artal Group held 111 positions worth $2.85B, up 4.9% from $2.72B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Artal Group deployed $223M of net new capital in Q4 2014, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was MetLife: 448,800 shares worth $21.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Alibaba, an estimated $12.8M trimmed.

  • Artal Group's largest Q4 2014 buy was MetLife: 448,800 shares worth $21.6M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q4 2014, an estimated $172M increase.
  • Artal Group's biggest Q4 2014 reduction was Alibaba, cutting an estimated $12.8M.
  • Artal Group fully exited AUXILIUM PHARAMCEUTICALS INC in Q4 2014, selling an estimated $32.6M.
  • Artal Group's ten largest holdings make up 64% of its $2.85B portfolio in Q4 2014.
  • Artal Group opened 25 new positions and closed 26 in Q4 2014.
  • Artal Group's portfolio value rose 4.9% quarter-over-quarter to $2.85B.

Based on Artal Group's 13F filing for Q4 2014, filed 13 Feb 2015.